Amidi Maryam, Romeijn Stefan G, Borchard Gerrit, Junginger Hans E, Hennink Wim E, Jiskoot Wim
Department of Pharmaceutical Technology, Leiden/Amsterdam Center for Drug Research (LACDR), Leiden University, P.O. Box 9502, 2300 RA Leiden, The Netherlands.
J Control Release. 2006 Mar 10;111(1-2):107-16. doi: 10.1016/j.jconrel.2005.11.014. Epub 2005 Dec 27.
In this study, the potential of N-trimethyl chitosan (TMC) nanoparticles as a carrier system for the nasal delivery of proteins was investigated. TMC nanoparticles were prepared by ionic crosslinking of TMC solution (with or without ovalbumin) with tripolyphosphate, at ambient temperature while stirring. The size, zeta-potential and morphology of the nanoparticles were investigated as a function of the preparation conditions. Protein loading, protein integrity and protein release were studied. The toxicity of the TMC nanoparticles was tested by ciliary beat frequency measurements of chicken embryo trachea and in vitro cytotoxicity assays. The in vivo uptake of FITC-albumin-loaded TMC nanoparticles by nasal epithelia tissue in rats was studied by confocal laser scanning microscopy. The nanoparticles had an average size of about 350 nm and a positive zeta-potential. They showed a loading efficiency up to 95% and a loading capacity up to 50% (w/w). The integrity of the entrapped ovalbumin was preserved. Release studies showed that more than 70% of the protein remained associated with the TMC nanoparticles for at least 3 h on incubation in PBS (pH 7.4) at 37 degrees C. Cytotoxicity tests with Calu-3 cells showed no toxic effects of the nanoparticles, whereas a partially reversible cilio-inhibiting effect on the ciliary beat frequency of chicken trachea was observed. In vivo uptake studies indicated the transport of FITC-albumin-associated TMC nanoparticles across the nasal mucosa. In conclusion, TMC nanoparticles are a potential new delivery system for transport of proteins through the nasal mucosa.
在本研究中,对N-三甲基壳聚糖(TMC)纳米颗粒作为蛋白质鼻腔给药载体系统的潜力进行了研究。通过在室温搅拌条件下,将TMC溶液(含或不含卵清蛋白)与三聚磷酸进行离子交联来制备TMC纳米颗粒。研究了纳米颗粒的尺寸、zeta电位和形态与制备条件的关系。对蛋白质负载量、蛋白质完整性和蛋白质释放进行了研究。通过鸡胚气管的纤毛搏动频率测量和体外细胞毒性试验测试了TMC纳米颗粒的毒性。利用共聚焦激光扫描显微镜研究了大鼠鼻腔上皮组织对载有FITC-白蛋白的TMC纳米颗粒的体内摄取情况。纳米颗粒的平均尺寸约为350 nm,zeta电位为正。它们的负载效率高达95%,负载量高达50%(w/w)。包裹的卵清蛋白的完整性得以保留。释放研究表明,在37℃的PBS(pH 7.4)中孵育至少3小时后,超过70%的蛋白质仍与TMC纳米颗粒结合。对Calu-3细胞的细胞毒性试验表明纳米颗粒无毒性作用,而观察到对鸡气管纤毛搏动频率有部分可逆的纤毛抑制作用。体内摄取研究表明,载有FITC-白蛋白的TMC纳米颗粒可穿过鼻黏膜。总之,TMC纳米颗粒是一种通过鼻黏膜转运蛋白质的潜在新型给药系统。